Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...
Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...
With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...
Morgan Stanley initiated coverage of GSK (GSK) with an Equal Weight rating and 1,450 GBp price target The shares trade at an inexpensive ...
A TASKFORCE will aim to allocate £2 million to a successful project in Ulverston by June as a ‘lasting legacy’ from a ...
LSE:GSK Earnings and Revenue History February 12th 2025 How Do Unusual Items Influence Profit? Importantly, our data ...
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
To join the GSK class action, go to https://rosenlegal.com/submit-form/?case_id=34609 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class ...
Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) reflecting updated views and recent competitive ...
After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback